Mundo Sano leads an important advance in public health with the approval in Ghana of a new combined drug for the treatment of geohelminths, a parasitic disease that affects millions of people worldwide. It is an innovative co-formulation that combines albendazole, used to eliminate common intestinal parasites, and ivermectin, effective against more resistant species such as Strongyloides and Trichuris, in a single tablet that improves therapeutic efficacy and simplifies its administration in mass campaigns.
Regulatory approval in Ghana represents a milestone that culminates more than 15 years of research and sustained work driven by Mundo Sano in partnership with various scientific and institutional actors. This combination allows for a more comprehensive approach to parasitic infections, optimizes treatments, and facilitates their implementation in neglected disease control and elimination programs.
This advance also opens the door to new clinical and operational studies, such as the REALISE study that will be conducted in Kenya and Ghana, with the aim of evaluating the impact of the co-formulation in real public health contexts. With this achievement, Mundo Sano reinforces its commitment to the development of innovative and accessible solutions to improve the quality of life of vulnerable populations and advance the global fight against parasitic diseases.
Mundo Sano drives an advance in public health with the approval in Ghana of an innovative combined drug for the treatment of geohelminths and parasitic diseases.